

Introduction

Blue Wave Therapeutics GmbH is an innovative early-stage radiopharmaceutical company dedicated to developing novel targeted radiotherapy for treating hard to treat solid tumors, with an initial focus on glioblastoma multiforme (GBM).

Problem


Glioblastoma multiforme is the most common primary malignant brain tumor, accounting for 77-81% of all malignant central nervous system tumors. GBM grows rapidly, with tumor size doubling in just 10 days. The current standard of care offers limited benefit to GBM patients: surgery is not effective and patients have to wait two months after surgery before chemo-radiation therapy is started, which gives tumor cells the time to grow back. The 5-year survival rate is below 10%; 98% of GBM patients ultimately succumbing to the disease.

Solution

Blue Wave Therapeutics' proprietary radioactive biopolymer platform can selectively kill tumor cells using alginate nanoparticles coated with a binding peptide to deliver a radionuclide payload specifically to targeted tumor cells. Our technology addresses the limitations of current treatments by starting the radiation of the remaining tumor cells with extremely effective alpha-radiation immediately after surgery.

Product

ARAspheres delivers a potent alpha-emitting radionuclide, Actinium-225, directly to brain tumor cells via alginate nanoparticles carrying a targeting peptide that enables specific binding to glioblastoma cells. ARAspheres' precision maximizes efficacy, while minimizing damage to healthy tissue.



Key Development Milestones and Future Roadmap

- 2024: Validation of Prototype Labeling and Stability
- 2025: Completion of Toxicity, Biodistribution, and Efficacy studies in animal models
- 2026: Preparation for IND application and GMP manufacturing scale-up
- 2027: Initiation of Phase I/IIa clinical trials
- 2029: Potential M&A/licensing deal pending clinical proof-of-concept (PoC)
- 2032+: Regulatory approvals and commercialization via pharmaceutical partners

Market Opportunity

According to Global Data's patient-based forecast, the GBM market across the eight major pharmaceutical markets (US, Switzerland, Japan, Germany, France, Italy, Spain, and the UK) is projected to reach \$3.1 billion in annual sales by 2031. GBM is an orphan indication in the US, EU, and Japan, with an annual incidence of 3-5 cases per 100,000 people. Worldwide incidence is 80,000 GBM newly diagnosed cases/year.

Business Model and Revenue Strategy

Blue Wave's strategy is to generate value through strategic partnerships with pharmaceutical companies. The company plans to achieve a successful exit through a merger and acquisition deal with a large biopharmaceutical company following demonstration of the clinical Proof of Concept (PoC), i.e., after completion of the phase I/IIa clinical trial, expected in 2029. Revenues will come from licensing deals. Future commercialization will be driven by biotech partnerships, ensuring broad patient access while maximizing shareholder value.

Funding Requirements and Use of Funds

The company is currently seeking CHF 1.5M in seed funding. These funds will enable completion of IND-enabling studies and engagement of regulatory agencies, bringing us closer to IND and clinical stage. Target close Q3 2025.

Defining a New Era in Cancer Treatment with Targeted Radiotherapy

Company

Founded in 2021, the company is headquartered in Switzerland, with a Norwegian subsidiary overseeing early-stage R&D. Blue Wave is built on a strong scientific foundation, leveraging decades of expertise from its co-founders in radiopharmaceuticals, drug delivery, and oncology research.

Technology Platform

Blue Wave Therapeutics' proprietary radioactive biopolymer platform can selectively kill tumor cells using alginate nanoparticles coated with a binding peptide to selectively deliver a radionuclide payload to targeted tumor cells. The IP covers the use of various peptides and different radionuclides, making the platform highly scalable for targeting a wide range of solid tumors.

Lead Product Candidate

Blue Wave Therapeutics is advancing its first product candidate, ²²⁵Ac-RGD-Alginate nanospheres (ARAspheres), through preclinical development to demonstrate proof of concept in glioblastoma GBM, the most common and deadliest type of brain cancer.

Funding

To date, Blue Wave has raised CHF 700K from founders, angel investors, and a strategic partner, alongside a CHF 1.3M non-dilutive grant from the Norwegian Research Council. The company is seeking CHF 1.5-5M in Seed funding (2025-2026), followed by a CHF 15-20M Series A (2027) to fund clinical trials and support regulatory submissions.

Management

Blue Wave Therapeutics' Management Board consists of five members: Marco G. Renoldi, MD – Chief Executive Officer, Michael Dornish, PhD – Co-founder & Chief Scientific Officer, Jostein Dahle, PhD – Co-founder & Chief Technology Officer. Luca Sereni, MBA – Co-founder & Chief Operating Officer, Stefania Poli, M.Psych. – Chief People Officer.



Contact

Blue Wave Therapeutics GmbH

Breitenstrasse 85 c, 8832 Wilen b. Wollerau
Switzerland (until April 30)
Kreuzstrasse 4, 4123 Allschwil, Switzerland
(from May 1)
Email
marco.renoldi@bluewavetherapeutics.com
info@bluewavetherapeutics.com